Loading stock data…
Adicet Bio, Inc. (ACET)
$9.73+0.14 (+1.46%)
After Hours$9.85+0.12 (+1.23%)· Last close Sep 8
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Adicet Bio, Inc. in the Healthcare sector is trading at $9.73 with a market capitalization of $89M. Wall Street consensus targets $33.17 (6 analysts), implying a +240.9% move over the next 12 months. The stock is currently 44% below its 52-week high of $17.44, remaining 20.6% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +240.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$21.57M↑ | -$31.89M↓ | -$27.95M↑ | -$32.39M↓ | -$29.89M |
| Net Income | -$20.24M↑ | -$30.52M↓ | -$26.86M↑ | -$31.22M↓ | -$28.21M |
Peer Comparison
JNJUNHPFE
Fundamentals
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel),...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$88.84M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.59
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-82.38%
Volume
Today's trading volume
81,840
Recent News
Wall Street Analysts See a 258.21% Upside in Adicet Bio (ACET): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 258.2% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Here is how Adicet Bio, Inc. (ACET) and Centene (CNC) have performed compared to their sector so far this year.
Here's Why You Should Add ACET Stock to Your Portfolio Now
Adicet Bio advances prula-cel in autoimmune diseases while pursuing new opportunities in prostate cancer and in vivo CAR-T.
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Here is how Adicet Bio, Inc. (ACET) and Agilent Technologies (A) have performed compared to their sector so far this year.
Wall Street Analysts Think Adicet Bio (ACET) Could Surge 301.57%: Read This Before Placing a Bet
The consensus price target hints at a 301.6% upside potential for Adicet Bio (ACET). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.